577 - Acceptability, Feasibility and Appropriateness of the Mobile Outreach Retention and Engagement (MORE) Program and Home Long-Acting Cabotegravir/Rilpivirine (CAB+RPV LA) Injections for People with HIV (PWH) Experiencing Adherence Challenges at Whitman-Walker Health in Washington D.C.

Presenting Author(s)

• 

  Megan Dieterich, MPH, MMSc, PA-C

  Whitman-Walker Institute
  Washington DC, District of Columbia, United States

  Slides

Co-Author(s)

• RP

  Rupa Patel
• MR

  Maria Rybicki-Newman, PhD

  Manager of Community & Qualitative Research
  Whitman-Walker Institute
  Washington, District of Columbia, United States
• KR

  Keyerra Richardson, MPH

  Clinical Research Manager
  Whitman-Walker Institute
  Washington, District of Columbia, United States
• ES

  Eleanor Sarkodie, MPH

  Director of Data Science
  The Institute for Health Research & Policy at Whitman-Walker
  Washington, District of Columbia, United States
• JS

  Janelle Schrag, MPH

  Director of Research Projects
  Whitman-Walker Institute
  Washington, District of Columbia, United States
• RB

  Robert Bangert, LICSW

  Senior Manager of Care Navigation
  Whitman-Walker Health
  Washington, District of Columbia, United States
• CK

  Chris Kubaska, BA

  Mobile Care Navigator
  Whitman-Walker Health
  Washington, District of Columbia, United States
• LB

  Lauren Brittingham, BA

  Mobile Care Navigator
  Whitman-Walker Health
  Washington, District of Columbia, United States
• MD

  Meghan Davies, MPH

  Chief Operating Officer
  Whitman-Walker Health
  Washington, District of Columbia, United States
• NS

  Namrata Shah, MD

  Medical Director of Research
  Whitman-Walker Institute
  Washington, District of Columbia, United States
• HR

  H. Jonathon Rendina, PhD

  Senior Director of Research
  Whitman-Walker Institute
  Washington, District of Columbia, United States